PUBLISHER: KuicK Research | PRODUCT CODE: 1484104
PUBLISHER: KuicK Research | PRODUCT CODE: 1484104
Global GPRC5D Targeting Drugs Market Opportunity & Clinical Trials Insight 2024
Global GPRC5D Targeting Drugs Market Opportunity & Clinical Trials Insight 2024 Report Highlights:
- Global GPRC5D Targeting Drugs Market Opportunity: > USD 1500 Million
- Approved GPRC5D Targeting Drugs In Market: 1 Drug (Talvey)
- Approved Drug Dosage, Pricing & Sales Insight
- GPRC5D Targeted Drugs Clinical Trials Insight By Company, Country, Indication & Phase
- Insight On More Than 15 Drug In Clinical Trials
- Platforms For Developing Advanced GPRC5D Therapy
In the pursuit for newfangled targeted therapies, G protein-coupled receptor class C group 5 member D or GPRC5D, an orphan G protein-coupled receptor, that has recently emerged as a promising therapeutic target for various diseases prevalent. GPRC5D is a plausible target in the realm of cancer care, particularly for the treatment of hematologic malignancies such as multiple myeloma. Importantly, GPRC5D expression is predominantly restricted to plasma cells, with minimal presence in normal tissues, making it an ideal target for therapeutic intervention due to its specificity.
Currently, only one GPRC5D targeting therapy, Talvey, has been approved by FDA, in August 2003, as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma (RRMM) who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 antibody and have demonstrated disease progression on the last therapy. The upcoming year in the global market is anticipated to witness the advent of more GPRC5D therapies in future.
Nevertheless, copious research and development in addition to preclinical studies are ongoing in the GPRC5D targeting therapies domain. The aim of these studies is developed an advanced, groundbreaking and novel GPRC5D therapy for the management of cancer, chiefly multiple myeloma and other diseases. For instance, OriCell Therapeutics has begun a phase I/II, open-label, multicenter study in order to assess the safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of anti-GPRC5D CAR-T cell product (OriCAR-017) in subjects with relapsed/refractory multiple myeloma in April 2024.
Recent advancements in GPRC5D targeting therapies have generated significant interest and excitement within the medical community. These therapies include a variety of innovative approaches such as monoclonal antibodies, antibody-drug conjugates (ADCs), and chimeric antigen receptor (CAR) T-cell therapies. Each of these modalities leverages the unique expression pattern of GPRC5D to selectively target and eradicate malignant cells while sparing normal tissues, thus potentially offering a more favorable safety profile compared to traditional treatments.
Amid all GPRC5D targeting therapeutic approaches, CAR T-cell therapies and bispecific antibodies are most used methods for the treatment of multiple myeloma as these modalities have shown particularly remarkable results. Introductory preclinical studies have exemplified that using CAR T cells coupled with bispecific antibody targeting GPRC5D can induce intense and durable remissions in patients with relapsed or refractory multiple myeloma. This is especially significant given the typically poor prognosis and limited treatment options for this patient population.
Interalia, the clinical development of GPRC5D targeting therapies is being rigorously pursued through a series of clinical trials designed to assess their safety, tolerability, and efficacy. Such as, Jiangsu Simcere Pharmaceutical in collaboration with Shanghai Xianxiang Medical Technology is planning to commence a phase 1 clinical trial, open-label, multicenter study to assess the safety, tolerability, effectiveness, and pharmacokinetics of SIM0500 in adult patients with relapsed or resistant multiple myeloma by May 2024.
These findings suggest that GPRC5D targeting therapies could potentially become a cornerstone in the treatment paradigm for multiple myeloma. Furthermore, the specificity of GPRC5D targeting therapies for plasma cells minimizes off target effects, which translates into a more manageable side effect profile for patients. This is a crucial consideration in cancer treatment, where treatment related toxicity can significantly impact the quality of life and overall outcomes for patients.
Several biopharmaceutical companies, such as AstraZeneca, Bristol Myers Squibb, Genmab, Johnson & Johnson, Roche and many more are actively engaged in the development of GPRC5D targeting therapies, with a focus on CAR T-cell products, monoclonal antibodies, and antibody drug conjugates.
Coupled with this, one of the fundamental prime movers which aid to expand the market of global GPRC5D targeting therapy is augmenting collaboration with global partners as well as expedited clinical trial approvals. For instance, in May 2023, LaNova Medicines, based in China, has signed a license agreement with UK based AstraZeneca Company to advance LaNova GPRC5D contender, LM-305. As per licensing agreement, AstraZeneca will have the solitary universal right to conduct research, develop and launch LM-305 in market.
In summary, GPRC5D targeting therapies represent a cutting-edge advancement in the treatment of multiple myeloma. Their development is driven by the unique expression pattern of GPRC5D, which allows for highly specific targeting of malignant plasma cells. As clinical trials continue to advance, there is optimism that these therapies will provide significant clinical benefits to patients, addressing a critical unmet need in the management of multiple myeloma along with other diseases in future.
Table of Contents
1. GPRC5D Targeting: A New Frontier in Therapeutic Advancements
- 1.1 Overview of GPRC5D
- 1.2 Clinical Evolution of GPRC5D Therapy
- 1.3 Need For GPRC5D Targeting Therapy
2. Role Of GPRC5D in Prognosis
3. GPRC5D Targeting Therapeutic Strategies
- 3.1 Monoclonal Antibody
- 3.2 Antibody Drug conjugate
- 3.3 Bispecific Antibody
- 3.4 Trispecific Antibody
- 3.5 CAR-T Cell Therapy
- 3.6 CAR-NK Therapy
- 3.7 Tumor Vaccine
4. GPRC5D Targeting Therapy By Indications: Clinical Trends & Innovations
- 4.1 Cancer
- 4.1.1 Hematological Cancers
- 4.1.2 Solid Tumors
- 4.2 Musculoskeletal Disease
5. Global GPRC5D Targeted Drugs Clinical Trials Overview
- 5.1 By Phase
- 5.2 By Country
- 5.3 By Company
- 5.4 By Indication
- 5.5 By Priority Status
- 5.6 Patient Segment
6. Global GPRC5D Current Market Trend & Developments
- 6.1 Current Market Outline
- 6.2 Future Market Outlook
7. Mapping GPRC5D Market: Regional Analysis
- 7.1 US
- 7.2 China
- 7.3 Europe
8. Global GPRC5D Targeting Drugs - Overview, Pricing, & Dosing Analysis
- 8.1 Talvey (Talquetamab)
- 8.1.1 Overview
- 8.1.2 Pricing & Dosing
- 8.2 Sales Analysis & Forecast
9. Global GPRC5D Targeted Drugs Clinical Trials Insight By Company, Country, Indication & Phase
- 9.1 Preclinical
- 9.2 Phase I
- 9.3 Phase I/II
- 9.4 Phase II
10. Marketed GPRC5D Targeted Drugs Clinical Insight
11. Combinations Strategies To Advance GPRC5D Therapy
- 11.1 Immunotherapy
- 11.2 Targeted Therapy
- 11.3 Immunomodulatory Drugs
12. Platforms For Developing Advanced GPRC5D Therapy
- 12.1 MPS Antibody Discovery Platform
- 12.2 T-Cell Engager Polyspecific Antibody Technology Platform
- 12.3 OriCAR CAR-T Platform
- 12.4 CARcelerateTM Platform
- 12.5 LX-ADC(TM) - Next Generation ADC Platform
- 12.6 AnTenGager(TM) Platform
- 12.7 DuoBody Technology Platform
13. Global GPRC5D Therapy Market Dynamics
- 13.1 Market Drivers
- 13.2 Market Challenges
14. Competitive Landscape
- 14.1 AstraZeneca
- 14.2 Beijing Mabworks Biotech
- 14.3 Cell Inspire Bio( Sanqi Biotech )
- 14.4 Guangzhou Bio-gene Technology
- 14.5 Janssen Research & Development
- 14.6 Juno Therapeutics (BMS)
- 14.7 Nanjing Leads Biolabs
- 14.8 Sana Biotechnology
- 14.9 Simcere Pharmaceutical Group
- 14.10 Yake Biotechnology
List of Figures
- Figure 1-1: Overview to GPRC5D
- Figure 1-2: Need for GPRC5D Therapy
- Figure 3-1: Therapeutic Strategies to Target GPRC5D Protein
- Figure 3-2: Approved Bispecific Antibody (Talvey) Targeting GPRC5D & CD3
- Figure 3-3: JNJ-79635322 Phase I (NCT05652335) Study - Initiation & Completion Year
- Figure 3-4: OriC321 Phase I (NCT05325801) Study - Initiation & Completion Year
- Figure 4-1: Anti-GPRC5D CAR-T Phase I (NCT05749133) Study - Initiation & Completion Year
- Figure 4-2: Combination Studies Ongoing for GPRC5D therapy to Treat Hematological Cancer
- Figure 4-3: BCMA/GPRC5D double CAR-T (NCT06068400) Study - Initiation & Completion Year
- Figure 5-1: Global - GPRC5D Targeted Drugs Clinical Trials By Phase (Numbers), 2024
- Figure 5-2: Global - GPRC5D Targeted Drugs Clinical Trials By Country (Numbers), 2024
- Figure 5-3: Global - GPRC5D Targeted Drugs Clinical Trials By Company (Numbers), 2024
- Figure 5-4: Global - GPRC5D Targeted Drugs Clinical Trials By Indication (Numbers), 2024
- Figure 5-5: Global - GPRC5D Targeted Drugs Clinical Trials By Priority Status (Numbers), 2024
- Figure 5-6: Global - GPRC5D Targeted Drugs Clinical Trials By Patient Segment (Numbers), 2024
- Figure 6-1: Global: GPRC5D Targeting Drugs Market Forecast (US$ Million), 2024 & 2028
- Figure 7-1: MCARH109 WITH MCARH125 Phase I (NCT05431608) Study - Initiation & Completion Year
- Figure 7-2: Bristol Myers Squibb GPRC5D Therapy Pipeline
- Figure 7-3: BMS-986393 Phase II (NCT06297226) Study - Initiation & Completion Year
- Figure 7-4: Integral Molecule Trispecific Antibody
- Figure 7-5: CT071 Phase I/II (NCT06333509) Study - Initiation & Completion Year
- Figure 7-6: SIM0500 Phase I (NCT06375044) Study - Initiation & Completion Year
- Figure 7-7: IBI3003 Phase I/II (NCT06083207) Study - Initiation & Completion Year
- Figure 7-8: AZD0305 Phase I/II (NCT06106945) Study - Initiation & Completion Year
- Figure 7-9: Forimtamig Phase I/II (NCT06055075) Study - Initiation & Completion Year
- Figure 7-10: Talvey - Approval Year by Region
- Figure 7-11: Talvey - Cost per Subcutaneous Solution & Supply of 2 mg/mL (US$), May'2024
- Figure 7-12: Talvey - Cost per Subcutaneous Solution & Supply of 40 mg/mL (US$), May'2024
- Figure 11-1: Teclistamab with Talquetamab Phase I/II (NCT04586426) Study - Initiation & Completion Year
- Figure 11-2: Forimtamig with Carfilzomib/Daratumumab Phase I/II (NCT06055075) Study - Initiation & Completion Year
- Figure 12-1: Integral Molecular - MPS Antibody Discovery Platform
- Figure 12-2: Integral Molecular - Development of Trispecific Antibody Targeting GPRC5D
- Figure 12-3: Simcere Zaiming - T Cell Engager Polyspecific Antibody Technology Platform
- Figure 12-4: LaNova Medicines - LX-ADC(TM) Next Generation ADC Platform
- Figure 12-5: Antengene - AnTenGager(TM) Platform
- Figure 12-6: Genmab - DuoBody Technology
List of Tables
- Table 3-1: CAR-T Therapy Approaches Targeting GPRC5D
- Table 4-1: GPRC5D Targeting Therapies for Hematological Cancers
- Table 7-1: Talvey - Weekly Dosing Schedule
- Table 7-2: Talvey - Biweekly (Every 2 Weeks) Dosing Schedule
- Table 7-3: Recommendations for Restarting Talvey after Dose Delay - Weekly Dosing Schedule
- Table 7-4: Recommendations for Restarting Talvey after Dose Delay - Biweekly (Every 2 Weeks) Dosing Schedule
- Table 7-5: Talvey - Recommendations for Management of Cytokine Release Syndrome (CRS)
- Table 7-6: Talvey - Recommendations for Management of Immune effector cell-associated neurotoxicity syndrome (ICANS)
- Table 7-7: Talvey - Recommendations for Management of Neurologic Toxicity (excluding ICANS)
- Table 7-8: Talvey - Recommended Dose Modifications for Other Adverse Reactions
